|
|
Perrigo Company Plc (NYSE: PRGO) |
|
Price: $28.4350
$0.37 
1.300%
|
| Day's High:
| $28.6177
| Week Perf:
| 0.34 %
|
| Day's Low: |
$ 28.02 |
30 Day Perf: |
8.99 % |
| Volume (M): |
238 |
52 Wk High: |
$ 34.60 |
| Volume (M$): |
$ 6,753 |
52 Wk Avg: |
$28.88 |
| Open: |
$28.10 |
52 Wk Low: |
$23.89 |
|
|
| Market Capitalization (Millions $) |
3,910 |
| Shares
Outstanding (Millions) |
138 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
4,392 |
| Net Income (TTM) (Millions $) |
-160 |
| Cash Flow (TTM) (Millions $) |
865 |
| Capital Exp. (TTM) (Millions $) |
107 |
Perrigo Company Plc
Perrigo Company PLC is an Irish-based international pharmaceutical and consumer health company that produces a wide range of prescription drugs, generic drugs, and over-the-counter (OTC) consumer healthcare products. The company is headquartered in Dublin, Ireland, and has operations in over 30 countries around the world. Perrigo Company PLC is considered to be one of the largest manufacturers of private label OTC pharmaceutical products in the world.
History
Perrigo Company PLC was first established in 1887 as a small grocery store in Allegan, Michigan. In the early 1900s, the company expanded into the manufacture of prescription drugs and vitamins. In the 1980s, Perrigo began manufacturing private label OTC medications, which became the cornerstone of its business.
In 2013, the company acquired Elan Corporation, a biotechnology company headquartered in Irish. The acquisition allowed Perrigo to move its tax domicile to Ireland, a move that became controversial and absorbed considerable public attention.
Products
Perrigo Company PLC's products are available in various forms, including tablets, capsules, creams, liquids, sprays, and gels. The company produces a wide range of products, including prescription medications, generic drugs, and OTC consumer healthcare products. Some of its most popular brands include Prevacid (a proton pump inhibitor for the treatment of acid reflux), Rogaine (a hair growth stimulant), and Claritin (an allergy medication).
Perrigo also manufactures private label products for retailers and other companies, including Walmarts and Target store brands. Some of the most popular OTC products that the company produces for retailers include pain relievers, cold and cough medications, and vitamins.
Organizational Structure
Perrigo Company PLC's organizational structure consists of several business units, including Consumer Healthcare Americas, Consumer Healthcare International, Rx Pharmaceuticals, and Specialty Science. The Consumer Healthcare Americas unit is responsible for the development, manufacture, and distribution of OTC consumer healthcare products in North and South America. The Consumer Healthcare International unit is responsible for the development, manufacture, and distribution of OTC products in Europe, Australia, and other international markets.
The Rx Pharmaceuticals unit is responsible for the development and manufacture of prescription, generic, and specialty drugs. The Specialty Sciences unit is responsible for the development of over-the-counter and prescription healthcare products for specialty healthcare communities.
Financial Information
Perrigo Company PLC is a publicly traded company listed on the New York Stock Exchange under the symbol "PRGO." As of June 2021, the company had a market cap of approximately $5 billion. In 2020, the company reported revenue of $5.1 billion, with the majority of its revenue coming from its Consumer Healthcare business units. The company's net income in 2020 was $261 million.
Controversies
In recent years, Perrigo Company PLC has been the subject of several controversies related to its products and business practices. Some of the most notable controversies include a recall of its ranitidine product (a medication used to treat GERD and peptic ulcers) due to potential contamination, lawsuits related to the company's pricing practices, and a $1.9 billion tax liability dispute with the Irish government. The company has denied any wrongdoing in each of these cases.
Company Address: The Sharp Building, Dublin 2, 0
Company Phone Number: 7094000 Stock Exchange / Ticker: NYSE PRGO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Perrigo Company Plc
The financial period ending March 30, 2024, brought positive results for Perrigo Company Plc, as they were able to turn the tide from fading revenue to profits. The company displayed an income per share of $0.01, in contrast to a loss of $-0.02 per share in the previous fiscal period. Although revenue fell by -8.393% to $1.08 billion from $1.18 billion in the previous year's Q1, it is still a noteworthy improvement.
In the previous financial reporting period, the Major Pharmaceutical Preparations company experienced revenue of $1.16 billion and a bottom line loss of $-0.24 per share. However, in the recent financial period, Perrigo Company Plc achieved a net income of $2.000 million, showcasing a significant improvement compared to a net loss of $-3.000 million in the same period a year ago. A crucial contributor to this success was the $102.70 million in provisions on income taxes that the company obtained.
|
| Perrigo Company Plc
Perrigo Company Plc Faces Challenges in Q4 2023 but Shows Signs of Potential
Perrigo Company Plc, a major pharmaceutical preparations company, recently released its financial results for the October to December 31, 2023 time-frame. While the company experienced a decline in earnings per share and a net shortfall, there are some promising indicators that point towards future growth and stability.
For the mentioned period, Perrigo Company Plc reported a shortfall per share of $-0.24, an increase from the $-0.17 reported a year ago. Additionally, earnings per share fell from $0.10 in the previous reporting period, suggesting some challenges in profitability. However, it is important to note that the company managed to reduce its shortfall per share significantly from the previous fiscal year, where it stood at $-1.04.
|
| Perrigo Company Plc
Perrigo Company Plc (PRGO) has showcased impressive financial results for the fiscal period ending September 30, 2023, signifying promising growth prospects for its investors. The company reported positive profits of $0.10 per share, a significant improvement from the loss of $-0.37 per share a year earlier. Additionally, the earnings-per-share (EPS) surged by an impressive 66.67% from $0.06 per share in the prior reporting season.
One of the key highlights of Perrigo's performance lies in its revenue growth. While the increase was slight at 2.118%, with the company's revenue reaching $1.12 billion compared to $1.10 billion in the same period the previous year, it is still a positive achievement. Furthermore, although there was a sequential decrease of -5.851% from $1.19 billion, the company's top-line improvement in the third quarter of 2023 outperforms its Major Pharmaceutical Preparations sector peers, who only experienced a 1.86% revenue increase during the same period.
|
| Perrigo Company Plc
Perrigo Company Plc Reports Turnaround in Q2 2023, Showing Signs of Growth
Perrigo Company Plc, a major player in the pharmaceutical preparations industry, has reported impressive financial results for the second quarter of 2023. The company has managed to turn a profit, with Income per Share (EPS) standing at $0.06 per share. This is a significant improvement compared to the same quarter last year, where the company reported a loss of $0.48 per share. Additionally, Perrigo Company Plc's EPS turned positive from the previous quarter's $-0.02 per share.
The company's revenue also demonstrated positive growth, increasing by 6.413% to $1.19 billion from $1.12 billion in the same quarter last year. On a sequential basis, revenue grew by 1.033% from $1.18 billion. This growth outperformed most of Perrigo Company Plc's major competitors in the pharmaceutical preparations industry, highlighting the company's strong performance in a challenging market.
|
| Perrigo Company Plc
Perrigo Company Plc, a leading pharmaceutical preparations company, recently reported its financial performance for the time frame of February to April 01 2023. While the company saw some positive growth in revenue, it also faced challenges in terms of diminishing returns and increasing net deficit.
In terms of revenue, Perrigo Company Plc saw a growth of 6.951% to $1.18 billion from $1.10 billion in the same reporting period a year prior. Sequentially, revenue grew by 2.294% from $1.16 billion. This is a promising sign for the company, as it indicates that the business is growing and expanding.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.17 $ |
| Revenues (TTM) |
31.94 $
|
| Cash Flow (TTM) |
6.29 $ |
| Cash |
10.64 $
|
| Book Value |
33.21 $
|
| Dividend (TTM) |
1.09 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.17 $
|
| Revenues (TTM) |
31.94 $ |
| Cash Flow (TTM) |
6.29 $ |
| Cash |
10.64 $
|
| Book Value |
33.21 $ |
| Dividend (TTM) |
1.09 $ |
|
|
| |
| CSCA |
|
 61.73 % |
of total Revenue |
| CSCA Nutrition |
|
11.69 % |
of total Revenue |
| CSCA Upper Respiratory |
|
11.12 % |
of total Revenue |
| CSCA Digestive Health |
|
10.44 % |
of total Revenue |
| CSCA Pain and Sleep-Aids |
|
8.07 % |
of total Revenue |
| CSCA Healthy Lifestyle |
|
7.44 % |
of total Revenue |
| CSCA Oral Care |
|
6.15 % |
of total Revenue |
| CSCA Skin Care |
|
4.77 % |
of total Revenue |
| CSCA Women s Health |
|
1.66 % |
of total Revenue |
| CSCA Vitamins Minerals and Supplements VMS |
|
0.32 % |
of total Revenue |
| CSCA Other CSCA |
|
0.08 % |
of total Revenue |
| CSCI |
|
38.28 % |
of total Revenue |
| CSCI Upper Respiratory |
|
7.92 % |
of total Revenue |
| CSCI Digestive Health |
|
0.83 % |
of total Revenue |
| CSCI Pain and Sleep-Aids |
|
5.23 % |
of total Revenue |
| CSCI Healthy Lifestyle |
|
4.89 % |
of total Revenue |
| CSCI Oral Care |
|
2.14 % |
of total Revenue |
| CSCI Skin Care |
|
8.37 % |
of total Revenue |
| CSCI Women s Health |
|
2.96 % |
of total Revenue |
| CSCI Vitamins Minerals and Supplements VMS |
|
3.95 % |
of total Revenue |
| CSCI Other CSCI |
|
1.99 % |
of total Revenue |
| U S |
|
60.41 % |
of total Revenue |
| Europe |
|
36.54 % |
of total Revenue |
| Ireland |
|
1.02 % |
of total Revenue |
| All other countries |
|
3.06 % |
of total Revenue |
|
|
0.08%